CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
hydroxyureadrug
Likely dose
Hydroxyurea 20 mg/kg/day orallyAI-extracted
Key inclusion· 6
  • ✓Histologically confirmed unresectable primary, recurrent, or residual benign meningioma
  • ✓Measurable disease by CT scan or MRI
  • ✓Disease progression within past 10 years OR progressive neurologic deficit within past 6 months
  • ✓Prior radiotherapy with subsequent disease progression OR refused radiotherapy
Key exclusion· 6
  • ✕Prior cytotoxic chemotherapy for meningioma
  • ✕Concurrent cytotoxic chemotherapy
  • ✕Concurrent antitumor hormonal therapy
  • ✕Concurrent radiotherapy

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00003590
NCT00003590Phase 2Completed
CompareCT.gov

Phase II Study of Hydroxyurea for Unresectable Meningioma

SWOG Cancer Research Network·interventional·Posted Jan 27, 2003·Updated May 20, 2016

In Brief

A Phase 2 clinical trial evaluating hydroxyurea for Adult Meningioma. Completed, enrolled 29 participants across 133 sites.

Detailed Summary

RATIONALE: Drugs used in chemotherapy such as hydroxyurea use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well hydroxyurea works in treating patients with unresectable benign meningioma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Meningioma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Eastern Cooperative Oncology Group

Timeline

Phase 2CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartNov 1, 1998
Primary CompletionDec 1, 2008
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 10.1 yearsPosted 23.4 years ago

Interventions

hydroxyureadrug

20 mg/kg/day PO